Strattera

Strattera

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Atomoxetine HCl
Indications/Uses
ADHD in childn ≥6 yr, adolescents & adults.
Dosage/Direction for Use
Adult, adolescent >70 kg & childn Initially 40 mg daily for at least 7 days. Maintenance: 80 mg daily. Max: 100 mg daily. Childn & adolescent up to 70 kg Initially 0.5 mg/kg daily for at least 7 days. Maintenance: 1.2 mg/kg daily. Max: 1.8 mg/kg daily.
Administration
May be taken with or without food: Swallow whole, do not open cap.
Contraindications
Hypersensitivity. Narrow-angle glaucoma. Severe CV or cerebrovascular disorders. History of pheochromocytoma. Concomitant use w/ MAOIs.
Special Precautions
Suicide-related behaviour, preexisting cardiac abnormalities. Measure heart rate & BP before, during, after treatment & at least every 6 mth. HTN, tachycardia, severe CV or cerebrovascular disorders; congenital or acquired long QT or family history of QT prolongation; orthostatic hypotension; preexisting psychotic or manic symptoms eg, hallucinations, delusional thinking, mania or agitation; aggressive behaviour, hostility or emotional lability; allergic reactions. Discontinued in patients w/ jaundice or laboratory evidence of liver injury; developing seizures. Long-term treatment. Monitor appearance or worsening of anxiety symptoms, depressed mood & depression or tics. Growth & development in childn & adolescents. Moderate or severe hepatic insufficiency. May affect ability to drive & use machines. Not to be used during pregnancy. Avoid use during lactation. Childn <6 yr.
Adverse Reactions
Decreased appetite; insomnia; headache; dry mouth, nausea; increased BP & heart rate. Agitation, decreased libido, sleep disorder, depression & depressed mood, anxiety; dizziness, dysgeusia, paraesthesia, somnolence, tremor; palpitations, tachycardia; flushing, hot flush; abdominal pain, constipation, dyspepsia, flatulence, vomiting; dermatitis, hyperhydrosis, rash; dysuria, pollakuria, urinary hesitation & retention; dysmenorrhea, ejaculation disorder, erectile dysfunction, prostatitis, male genital pain; asthenia, fatigue, lethargy, chills, feeling jittery, irritability, thirst; decreased wt.
Drug Interactions
MAOIs. Increased exposure w/ CYP2D6 inhibitors (fluoxetine, paroxetine) quinidine, terbinafine. Potentiation of CV effects w/ salbutamol or other β2-agonists. Increased risk of QT interval prolongation w/ other QT prolonging drugs eg, neuroleptics, class IA & III antiarrhythmics, moxifloxacin, erythromycin, methadone, mefloquine, TCAs, lithium or cisapride; thiazide diuretics; CYP2D6 inhibitors. Potential w/drawal seizures w/ benzodiazepines. Decreased effectiveness of antihypertensives or drugs used to treat HTN. Possible increased on BP w/ pressor agents. Additive or synergistic pharmacological effects by drugs that affect noradrenaline eg, imipramine, venlafaxine & mirtazapine, decongestants eg, pseudoephedrine or phenylephrine.
ATC Classification
N06BA09 - atomoxetine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.
Presentation/Packing
Form
Strattera cap 40 mg
Packing/Price
28's
Form
Strattera cap 25 mg
Packing/Price
28's
Form
Strattera cap 18 mg
Packing/Price
28's
Form
Strattera cap 60 mg
Packing/Price
28's
Form
Strattera cap 10 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in